155 related articles for article (PubMed ID: 30819189)
21. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.
Stark AP; Chang HH; Jung X; Moro A; Hertzer K; Xu M; Schmidt A; Hines OJ; Eibl G
Surgery; 2015 Dec; 158(6):1564-72. PubMed ID: 26297056
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
[TBL] [Abstract][Full Text] [Related]
23. Glycolysis regulates KRAS plasma membrane localization and function through defined glycosphingolipids.
Liu J; van der Hoeven R; Kattan WE; Chang JT; Montufar-Solis D; Chen W; Wong M; Zhou Y; Lebrilla CB; Hancock JF
Nat Commun; 2023 Jan; 14(1):465. PubMed ID: 36709325
[TBL] [Abstract][Full Text] [Related]
24. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.
Schneeweis C; Wirth M; Saur D; Reichert M; Schneider G
Small GTPases; 2018 Nov; 9(6):457-464. PubMed ID: 27880072
[TBL] [Abstract][Full Text] [Related]
26. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells.
Bailey JM; Hendley AM; Lafaro KJ; Pruski MA; Jones NC; Alsina J; Younes M; Maitra A; McAllister F; Iacobuzio-Donahue CA; Leach SD
Oncogene; 2016 Aug; 35(32):4282-8. PubMed ID: 26592447
[TBL] [Abstract][Full Text] [Related]
27. U1 Adaptors Suppress the
Tsang AT; Dudgeon C; Yi L; Yu X; Goraczniak R; Donohue K; Kogan S; Brenneman MA; Ho ES; Gunderson SI; Carpizo DR
Mol Cancer Ther; 2017 Aug; 16(8):1445-1455. PubMed ID: 28377488
[TBL] [Abstract][Full Text] [Related]
28. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
29. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
30. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer.
Hou P; Kapoor A; Zhang Q; Li J; Wu CJ; Li J; Lan Z; Tang M; Ma X; Ackroyd JJ; Kalluri R; Zhang J; Jiang S; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Jul; 10(7):1058-1077. PubMed ID: 32341020
[TBL] [Abstract][Full Text] [Related]
31. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
32. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.
Fujimura K; Wang H; Watson F; Klemke RL
Cancer Res; 2018 Mar; 78(6):1444-1456. PubMed ID: 29321164
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic KRAS signaling activates mTORC1 through COUP-TFII-mediated lactate production.
Byun JK; Park M; Yun JW; Lee J; Kim JS; Cho SJ; Lee YM; Lee IK; Choi YK; Park KG
EMBO Rep; 2019 Jun; 20(6):. PubMed ID: 30988000
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
[TBL] [Abstract][Full Text] [Related]
36. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
[TBL] [Abstract][Full Text] [Related]
37. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
38. RAGE maintains high levels of NFκB and oncogenic Kras activity in pancreatic cancer.
Azizan N; Suter MA; Liu Y; Logsdon CD
Biochem Biophys Res Commun; 2017 Nov; 493(1):592-597. PubMed ID: 28867179
[TBL] [Abstract][Full Text] [Related]
39. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.
Niu N; Lu P; Yang Y; He R; Zhang L; Shi J; Wu J; Yang M; Zhang ZG; Wang LW; Gao WQ; Habtezion A; Xiao GG; Sun Y; Li L; Xue J
Gut; 2020 Apr; 69(4):715-726. PubMed ID: 31300513
[TBL] [Abstract][Full Text] [Related]
40. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
